Copy Link
Thermo Fisher Scientific’s PPD clinical research business published a recent survey on predictions for biopharma and biotech industries in 20241. According to this survey, over a third of industry leaders consider big data which are generated to complement clinical trials as among the top five drug development trends of 2023. More than 40% say that they pursue real-world data (RWD) and evidence (RWE) as a top strategy in their trials1.
With the power of RWE to improve trial design, operations, and efficiency predicted to be harnessed more than ever in 20242, we present some tips in the infographic below for how best to complement your clinical trials with real-world research.
The persistent growth in the RWE market is fueled by rising demands for RWE capabilities within the life sciences industry. This year at Vitaccess, we have supported our clients to fulfil diverse research objectives through our extensive experience in designing and running real-world and patient-centered outcomes research, our strong and flexible in-house PCO, analytics, and localization teams, and our excellent relationships with patients, clinicians, and industry stakeholders. Drop us an email to arrange a chat for the new year – we’d be delighted to speak with you!
As we come to the end of 2023, we wish our clients, partners, and study participants a restful Christmas break and happy New Year.
By Fatemeh Amini
References
- https://www.ppd.com/blog/drug-development-predictions-trends-2024/
- https://www.grandviewresearch.com/industry-analysis/real-world-evidence-solutions-market-report#:~:text=b.-,The%20global%20real%20world%20evidence%20solutions%20market%20size%20was%20estimated,world%20evidence%20solutions%20market%20growth%3F
